TSTadashi Sato

Tadashi Sato

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tadashi Sato has a total of 114 co-authors. Here are the top co-authors by number of shared publications:

  • Kazuhisa Takahashi

    Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    7 shared publications
  • Kazuhisa Takahashi

    Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan

    6 shared publications
  • Kuniaki Seyama

    Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    6 shared publications
  • Hitomi Yoshikawa

    Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    5 shared publications
  • Kuniaki Seyama

    Division of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan

    5 shared publications
  • Yohei Suzuki

    Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

    5 shared publications

Latest Publications

  • Open Access

    Effectiveness of educational reinstruction on patient satisfaction and inhaler technique in Japanese patients with stable chronic obstructive pulmonary disease: A prospective, open-label, randomized controlled trial

    by Kimiko Horikoshi, Tadashi Sato, Mika Hayashi, Eriko Kuwasaki, Yuka Furudate, Megumi Minamoto, Tomomi Konuma, Takuto Iijima, Ryunosuke Okahara, Shuko Nojiri, et al.


  • miR-146a regulates emphysema formation and abnormal inflammation in the lungs of two mouse models

    by Hitomi Yoshikawa, Tadashi Sato, Kimiko Horikoshi, Moegi Komura, Naoko Arano Nitta, Aki Mitsui, Kengo Koike, Yuzo Kodama, Kazuhisa Takahashi

    This study demonstrates that miR-146a expression is upregulated in mouse lungs because of elastase- and CS-induced emphysema and that the inflammatory response by elastase or CS is enhanced in the lungs of miR-146a-KO mice than in those of control mice, resulting in the promotion of emphysema. This is the first study to evaluate the protective role of miR-146a in emphysema formation and the associated abnormal inflammatory response in different in vivo models.


  • Open Access

    Blood Eosinophil Count as a Predictive Biomarker of Chronic Obstructive Pulmonary Disease Exacerbation in a Real-World Setting

    by Moegi Komura, Tadashi Sato, Yohei Suzuki, Hitomi Yoshikawa, Naoko Arano Nitta, Mika Hayashi, Eriko Kuwasaki, Kimiko Horikoshi, Toshihiko Nishioki, Mikiko Mori, et al.

    Introduction. Chronic obstructive pulmonary disease (COPD) is the third leading cause of death, and COPD exacerbation worsens the prognosis. Eosinophilic airway inflammation is a COPD phenotype that causes COPD exacerbation and is correlated with peripheral blood eosinophil count. We analyzed real-world data of COPD patients to assess the risk factors of COPD exacerbation focusing on blood eosinophils. Materials and Methods. Patients with COPD who visited our hospital between January 1, 2018, and December 31, 2018, were recruited, and their background information, spirometry data, laboratory test results, and moderate-to-severe exacerbation events during the one-year follow-up period were collected from the electronic medical records and analyzed. The COPD exacerbation risk factors were assessed using univariate and multivariate logistic regression analyses. Results. Twenty-two of 271 (8.1%) patients experienced moderate-to-severe exacerbation. Patients with exacerbation showed worse pulmonary function, and we found that a high blood eosinophil count (≥350 cells/μL; ), low % FEV1 ( ), increase in white blood cell (≥9000 cells/μL; ), and use of home oxygen therapy ( ) were risk factors for future exacerbations. We also found a strong correlation between eosinophil count cut-offs and exacerbation risk (r = 0.89, ). On the other hand, there was no relation between exacerbation risk and inhalation therapy for COPD. Conclusion. In a real-world setting, peripheral blood eosinophil count could be a predictor of future COPD exacerbation.


  • Open Access

    Carcinoembryonic antigen levels in pancreatic juice are associated with histological subtypes of intraductal papillary mucinous neoplasm of the pancreas

    by Hiroshi Hayakawa, Mitsuharu Fukasawa, Shinichi Takano, Hiroko Shindo, Ei Takahashi, Satoshi Kawakami, Yoshimitsu Fukasawa, Natsuhiko Kuratomi, Tadashi Sato, Makoto Kadokura, et al.

    Background: The present study aimed to examine the correlation between preoperative carcinoembryonic antigen levels in pancreatic juice (PJ‐CEA) and the histological subtype of intraductal papillary mucinous neoplasm (IPMN).Methods: We enrolled IPMN patients who underwent endoscopic retrograde pancreatography between March 2002 and March 2018. Clinical factors associated with IPMN histological subtypes of 67 patients who underwent surgery were analyzed. Furthermore, the relationship between CEA immunohistochemistry findings and histological subtypes was investigated.Results: Median PJ‐CEA were 15 ng/ml in the gastric type, 150 ng/ml in the intestinal type, and 175 ng/ml in the pancreatobiliary type. Both intestinal and pancreatobiliary types had significantly higher PJ‐CEA than the gastric type (p = 0.001). In the analysis of histological subtype predictors, high PJ‐CEA (≥63 ng/ml) only showed a significant difference in multivariate analyses (95% confidence interval 4.8–70.2; p < 0.001). Immunohistochemistry findings revealed significantly higher CEA expression in the non‐gastric type than in the gastric type (p < 0.001). The non‐gastric type showed a significantly worse prognosis than the gastric type (p = 0.017).Conclusion: PJ‐CEA was an independent predictor of IPMN histological subtypes in a preoperative setting. High PJ‐CEA predict the non‐gastric type, while low PJ‐CEA predict the gastric type.


  • Open Access

    Propylene glycol, a component of electronic cigarette liquid, damages epithelial cells in human small airways

    by Moegi Komura, Tadashi Sato, Hitomi Yoshikawa, Naoko Arano Nitta, Yohei Suzuki, Kengo Koike, Yuzo Kodama, Kuniaki Seyama, Kazuhisa Takahashi

    Background: Electronic cigarettes (e-cigarettes) are used worldwide as a substitute for conventional cigarettes. Although they are primarily intended to support smoking cessation, e-cigarettes have been identified as a gateway to smoking habits for young people. Multiple recent reports have described the health effects of inhaling e-cigarettes. E-cigarette liquid (e-liquid) is mainly composed of propylene glycol (PG) and glycerol (Gly), and the aerosol generated by these devices primarily contains these two components. Thus, this study aimed to evaluate the effects of PG and Gly on human small airway epithelial cells (SAECs). Methods: SAECs were exposed to PG or Gly, and cell proliferation, cell viability, lactate dehydrogenase (LDH) release, DNA damage, cell cycle, and apoptosis were evaluated. Additionally, SAECs derived from chronic obstructive pulmonary disease (COPD) patients (COPD-SAECs) were investigated. Results: Exposure of SAECs to PG significantly inhibited proliferation (1%, PG, p = 0.021; 2–4% PG, p < 0.0001) and decreased cell viability (1–4% PG, p < 0.0001) in a concentration-dependent manner. Gly elicited similar effects but to a reduced degree as compared to the same concentration of PG. PG also increased LDH release in a concentration-dependent manner (3% PG, p = 0.0055; 4% PG, p < 0.0001), whereas Gly did not show a significant effect on LDH release. SAECs exposed to 4% PG contained more cells that were positive for phosphorylated histone H2AX (p < 0.0001), a marker of DNA damage, and an increased proportion of cells in the G1 phase (p < 0.0001) and increased p21 expression (p = 0.0005). Moreover, caspase 3/7-activated cells and cleaved poly (ADP-ribose) polymerase 1 expression were increased in SAECs exposed to 4% PG (p = 0.0054). Furthermore, comparing COPD-SAECs to SAECs without COPD in PG exposure, cell proliferation, cell viability, DNA damage and apoptosis were significantly greater in COPD-SAECs. Conclusion: PG damaged SAECs more than Gly. In addition, COPD-SAECs were more susceptible to PG than SAECs without COPD. Usage of e-cigarettes may be harmful to the respiratory system, especially in patients with COPD.


  • Exposure to the heated tobacco product IQOS generates apoptosis-mediated pulmonary emphysema in murine lungs

    by Naoko Arano Nitta, Tadashi Sato, Moegi Komura, Hitomi Yoshikawa, Yohei Suzuki, Aki Mitsui, Eriko Kuwasaki, Fumiyuki Takahashi, Yuzo Kodama, Kuniaki Seyama, et al.

    Pulmonary emphysema is predominantly caused by chronic exposure to cigarette smoke (CS). Novel tobacco substitutes, such as heated tobacco products (HTPs), have emerged as healthier alternatives to cigarettes. IQOS, the most popular HTP in Japan, is advertised as harmless compared with conventional cigarettes. Although some studies have reported its toxicity, few in vivo studies have been conducted. Here, 12-wk-old C57BL6/J male mice were divided into three groups and exposed to air (as control), IQOS aerosol, or CS for 6 mo. After exposure, the weight gain was significantly suppressed in the IQOS and CS groups compared with the control (−4.93 g; IQOS vs. air and −5.504 g; CS vs. air). The serum cotinine level was significantly higher in the IQOS group than in the control group. The neutrophils and lymphocyte count increased in the bronchoalveolar lavage fluid of the IQOS and CS groups compared with those in the control group. Chronic IQOS exposure induced pulmonary emphysema similar to that observed in the CS group. Furthermore, expression levels of the genes involved in the apoptosis-related pathways were significantly upregulated in the lungs of the IQOS-exposed mice. Cytochrome c, cleaved caspase-3, and cleaved poly (ADP-ribose) polymerase-1 were overexpressed in the IQOS group compared with the control. Single-stranded DNA and TdT-mediated dUTP nick-end labeling-positive alveolar septal cell count significantly increased in the IQOS group compared with the control. In conclusion, chronic exposure to IQOS aerosol induces pulmonary emphysema predominantly via apoptosis-related pathways. This suggests that HTPs are not completely safe tobacco products.


  • Open Access

    Protocol for assessing senescence-associated lung pathologies in mice

    by Koichiro Kawaguchi, Michihiro Hashimoto, Ryuta Mikawa, Azusa Asai, Tadashi Sato, Masataka Sugimoto


  • Open Access

    Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway

    by Motoyasu Kato, Fumiyuki Takahashi, Tadashi Sato, Yoichiro Mitsuishi, Ken Tajima, Hiroaki Ihara, Fariz Nurwidya, Hario Baskoro, Akiko Murakami, Isao Kobayashi, et al.

    Purpose: Idiopathic pulmonary fibrosis (IPF) is characterized by the accumulation of extracellular matrix (ECM) protein in the lungs. Transforming growth factor (TGF) β-induced ECM protein synthesis contributes to the development of IPF. Tranilast, an anti-allergy drug, suppresses TGFβ expression and inhibits interstitial renal fibrosis in animal models. However, the beneficial effects of tranilast or its mechanism as a therapy for pulmonary fibrosis have not been clarified. Methods: We investigated the in vitro effect of tranilast on ECM production and TGFβ/SMAD2 pathway in TGFβ 2-stimulated A549 human alveolar epithelial cells, using quantitative polymerase chain reaction, Western blotting, and immunofluorescence. In vitro observations were validated in the lungs of a murine pulmonary fibrosis model, which we developed by intravenous injection of bleomycin. Results: Treatment with tranilast suppressed the expression of ECM proteins, such as fibronectin and type IV collagen, and attenuated SMAD2 phosphorylation in TGFβ 2-stimulated A549 cells. In addition, based on a wound healing assay in these cells, tranilast significantly inhibited cell motility, with foci formation that comprised of ECM proteins. Histological analyses revealed that the administration of tranilast significantly attenuated lung fibrosis in mice. Furthermore, tranilast treatment significantly reduced levels of TGFβ, collagen, fibronectin, and phosphorylated SMAD2 in pulmonary fibrotic tissues in mice. Conclusion: These findings suggest that tranilast inhibits pulmonary fibrosis by suppressing TGFβ/SMAD2-mediated ECM protein production, presenting tranilast as a promising and novel anti-fibrotic agent for the treatment of IPF.